MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.670
-0.130
-3.42%
Opening 12:16 09/21 EDT
OPEN
3.750
PREV CLOSE
3.800
HIGH
3.750
LOW
3.640
VOLUME
356.36K
TURNOVER
--
52 WEEK HIGH
7.03
52 WEEK LOW
0.2310
MARKET CAP
142.65M
P/E (TTM)
-5.9868
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
Genprex hires Senior Vice President of IP and Licensing
Business Wire · 3h ago
This Biotech Appears to Have the Right Formula for Investors
After reviewing the rally, let's zero in one biotech name, Genprex, and where it appears to be going....GNPX
TheStreet.com · 09/09 20:25
LD Micro 360 Companies Set to Present this Week.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 09/02 21:36
Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs
Genprex appoints new Vice President of Regulatory Affairs
Business Wire · 09/02 13:17
Genprex to Present at The LD 500 Virtual Conference
Genprex's Chairman and CEO will present on September 1, 2020 at the LD 500 Virtual Conference
Business Wire · 08/26 12:17
Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020
Genprex's CEO will Present at the Proactive Investor Forum on August 4 at 1:40 p.m. ET
Business Wire · 07/31 12:17
Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show"
Business Wire · 07/30 13:16
STX, BCS among premarket losers
Seeking Alpha - Article · 07/29 12:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNPX stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 5.17M
% Owned: 13.31%
Shares Outstanding: 38.87M
TypeInstitutionsShares
Increased
15
1.12M
New
31
3.10M
Decreased
2
2.01K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.44%
Pharmaceuticals & Medical Research
-3.03%
Key Executives
Chairman/President/Chief Executive Officer/Secretary/Director
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Chief Operating Officer/Executive Vice President
Michael Redman
Executive Vice President
Catherine Vaczy
Independent Director
Brent Longnecker
Independent Director
Jose Moreno Toscano
Independent Director
William Wilson
Director
Will Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average GNPX stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Genprex Inc stock information, including NASDAQ:GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.